euroclinics (uk) limited
euroclinics (uk) limited Company Information
Company Number
04499876
Website
http://preventicum.co.ukRegistered Address
beechwood hall kingsmead road, high wycombe, buckinghamshire, HP11 1JL
Industry
General medical practice activities
Telephone
02076056900
Next Accounts Due
June 2024
Group Structure
View All
Shareholders
preventicum uk ltd 100%
euroclinics (uk) limited Estimated Valuation
The estimated valuation range for euroclinics (uk) limited, derived from financial data as of September 2022 and the most recent industry multiples, is between £0 to £5.1m
euroclinics (uk) limited Estimated Valuation
The estimated valuation range for euroclinics (uk) limited, derived from financial data as of September 2022 and the most recent industry multiples, is between £0 to £5.1m
euroclinics (uk) limited Estimated Valuation
The estimated valuation range for euroclinics (uk) limited, derived from financial data as of September 2022 and the most recent industry multiples, is between £0 to £5.1m
Get a detailed valuation report, edit figures and unlock valuation multiples.
Euroclinics (uk) Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Euroclinics (uk) Limited Overview
Euroclinics (uk) Limited is a live company located in buckinghamshire, HP11 1JL with a Companies House number of 04499876. It operates in the general medical practice activities sector, SIC Code 86210. Founded in July 2002, it's largest shareholder is preventicum uk ltd with a 100% stake. Euroclinics (uk) Limited is a mature, mid sized company, Pomanda has estimated its turnover at £6.2m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Euroclinics (uk) Limited Health Check
Pomanda's financial health check has awarded Euroclinics (Uk) Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 3 areas for improvement. Company Health Check FAQs
6 Strong
2 Regular
3 Weak
Size
annual sales of £6.2m, make it larger than the average company (£1.7m)
£6.2m - Euroclinics (uk) Limited
£1.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 6%, show it is growing at a similar rate (6.4%)
6% - Euroclinics (uk) Limited
6.4% - Industry AVG
Production
with a gross margin of 56.8%, this company has a lower cost of product (39.8%)
56.8% - Euroclinics (uk) Limited
39.8% - Industry AVG
Profitability
an operating margin of 13.2% make it more profitable than the average company (5.8%)
13.2% - Euroclinics (uk) Limited
5.8% - Industry AVG
Employees
with 18 employees, this is similar to the industry average (17)
18 - Euroclinics (uk) Limited
17 - Industry AVG
Pay Structure
on an average salary of £54.9k, the company has a higher pay structure (£28.2k)
£54.9k - Euroclinics (uk) Limited
£28.2k - Industry AVG
Efficiency
resulting in sales per employee of £343.3k, this is more efficient (£74.8k)
£343.3k - Euroclinics (uk) Limited
£74.8k - Industry AVG
Debtor Days
it gets paid by customers after 15 days, this is earlier than average (42 days)
15 days - Euroclinics (uk) Limited
42 days - Industry AVG
Creditor Days
its suppliers are paid after 91 days, this is slower than average (31 days)
91 days - Euroclinics (uk) Limited
31 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Euroclinics (uk) Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (40 weeks)
0 weeks - Euroclinics (uk) Limited
40 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 201.5%, this is a higher level of debt than the average (60.3%)
201.5% - Euroclinics (uk) Limited
60.3% - Industry AVG
euroclinics (uk) limited Credit Report and Business Information
Euroclinics (uk) Limited Competitor Analysis
Perform a competitor analysis for euroclinics (uk) limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
euroclinics (uk) limited Ownership
EUROCLINICS (UK) LIMITED group structure
Euroclinics (Uk) Limited has no subsidiary companies.
Ultimate parent company
THE DAMASK TRUST
#0071119
2 parents
EUROCLINICS (UK) LIMITED
04499876
euroclinics (uk) limited directors
Euroclinics (Uk) Limited currently has 2 directors. The longest serving directors include Mr Richard Bradford (Apr 2011) and Mr Steven Scott (Feb 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Richard Bradford | Bucks | 61 years | Apr 2011 | - | Director |
| Mr Steven Scott | 39 years | Feb 2022 | - | Director |
EUROCLINICS (UK) LIMITED financials
Euroclinics (Uk) Limited's latest turnover from September 2022 is £6.2 million and the company has net assets of -£2.4 million. According to their latest financial statements, Euroclinics (Uk) Limited has 18 employees and maintains cash reserves of £54 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 6,180,000 | 4,600,000 | 2,985,000 | 5,210,000 | 4,507,000 | 3,861,000 | 3,231,000 | 2,777,000 | 2,648,000 | 2,092,000 | 2,195,000 | 2,112,000 | 1,502,000 | 1,167,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 2,668,000 | 2,029,000 | 1,792,000 | 2,443,000 | 2,246,000 | 1,993,000 | 1,947,000 | 1,696,000 | 1,806,000 | 1,490,000 | 1,499,000 | 1,405,000 | 322,000 | 676,000 |
| Gross Profit | 3,512,000 | 2,571,000 | 1,193,000 | 2,767,000 | 2,261,000 | 1,868,000 | 1,284,000 | 1,081,000 | 842,000 | 602,000 | 696,000 | 707,000 | 1,180,000 | 491,000 |
| Admin Expenses | 2,696,000 | 2,483,000 | 2,806,000 | 2,290,000 | 1,778,000 | 1,463,000 | 878,000 | 913,000 | 603,000 | 642,000 | 588,000 | 615,000 | 1,520,000 | 815,000 |
| Operating Profit | 816,000 | 88,000 | -1,613,000 | 477,000 | 483,000 | 405,000 | 406,000 | 168,000 | 239,000 | -40,000 | 108,000 | 92,000 | -340,000 | -324,000 |
| Interest Payable | 31,000 | 35,000 | 103,000 | 159,000 | 39,000 | 38,000 | 76,000 | 34,000 | 32,000 | 22,000 | 19,000 | 26,000 | 3,000 | 0 |
| Interest Receivable | 6,000 | 0 | 0 | 0 | 0 | 0 | 0 | 57,000 | 0 | 0 | 0 | 1,000 | 0 | 0 |
| Pre-Tax Profit | 791,000 | 53,000 | -1,716,000 | 318,000 | 444,000 | 367,000 | 330,000 | 191,000 | 207,000 | -62,000 | 89,000 | 67,000 | -355,000 | -324,000 |
| Tax | -3,000 | 327,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16,000 | 0 | 0 | 0 | 0 |
| Profit After Tax | 788,000 | 380,000 | -1,716,000 | 318,000 | 444,000 | 367,000 | 330,000 | 191,000 | 207,000 | -46,000 | 89,000 | 67,000 | -355,000 | -324,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 788,000 | 380,000 | -1,716,000 | 318,000 | 444,000 | 367,000 | 330,000 | 191,000 | 207,000 | -46,000 | 89,000 | 67,000 | -355,000 | -324,000 |
| Employee Costs | 989,000 | 906,000 | 1,077,000 | 1,310,000 | 1,124,000 | 968,000 | 920,000 | 720,000 | 726,000 | 603,000 | 575,000 | 611,000 | 631,000 | 489,000 |
| Number Of Employees | 18 | 15 | 18 | 21 | 17 | 12 | 12 | 10 | 11 | 9 | 11 | 11 | 11 | 11 |
| EBITDA* | 816,000 | 88,000 | -1,613,000 | 477,000 | 483,000 | 405,000 | 406,000 | 168,000 | 239,000 | -40,000 | 108,000 | 92,000 | -340,000 | -324,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 1,525,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 1,525,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5,000 | 1,000 | 4,000 | 0 |
| Trade Debtors | 260,000 | 612,000 | 81,000 | 70,000 | 144,000 | 176,000 | 122,000 | 40,000 | 123,000 | 74,000 | 191,000 | 305,000 | 76,000 | 86,000 |
| Group Debtors | 404,000 | 251,000 | 0 | 2,530,000 | 3,720,000 | 3,540,000 | 3,223,000 | 3,380,000 | 3,006,000 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 111,000 | 19,000 | 29,000 | 18,000 | 32,000 | 2,000 | 14,000 | 3,000 | 2,000 | 25,000 | 19,000 | 15,000 | 16,000 | 24,000 |
| Cash | 54,000 | 71,000 | 222,000 | 110,000 | 198,000 | 86,000 | 99,000 | 87,000 | 122,000 | 1,455,000 | 543,000 | 175,000 | 2,000 | 38,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 829,000 | 953,000 | 332,000 | 2,728,000 | 4,094,000 | 3,804,000 | 3,458,000 | 3,510,000 | 3,253,000 | 1,554,000 | 758,000 | 496,000 | 98,000 | 148,000 |
| total assets | 2,354,000 | 953,000 | 332,000 | 2,728,000 | 4,094,000 | 3,804,000 | 3,458,000 | 3,510,000 | 3,253,000 | 1,554,000 | 758,000 | 496,000 | 98,000 | 148,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 337,000 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 670,000 | 414,000 | 257,000 | 272,000 | 242,000 | 290,000 | 71,000 | 342,000 | 84,000 | 97,000 | 65,000 | 54,000 | 67,000 | 76,000 |
| Group/Directors Accounts | 3,483,000 | 3,379,000 | 3,439,000 | 731,000 | 2,379,000 | 2,435,000 | 0 | 0 | 2,848,000 | 1,091,000 | 261,000 | 3,803,000 | 3,379,000 | 3,419,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 591,000 | 338,000 | 194,000 | 107,000 | 173,000 | 223,000 | 2,898,000 | 3,045,000 | 322,000 | 255,000 | 275,000 | 467,000 | 210,000 | 193,000 |
| total current liabilities | 4,744,000 | 4,131,000 | 3,890,000 | 1,110,000 | 2,794,000 | 2,948,000 | 2,969,000 | 3,387,000 | 3,254,000 | 1,443,000 | 601,000 | 4,324,000 | 3,993,000 | 3,688,000 |
| loans | 0 | 0 | 0 | 3,460,000 | 3,318,000 | 3,318,000 | 3,318,000 | 3,282,000 | 3,577,000 | 3,896,000 | 3,896,000 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 3,460,000 | 3,318,000 | 3,318,000 | 3,318,000 | 3,282,000 | 3,577,000 | 3,896,000 | 3,896,000 | 0 | 0 | 0 |
| total liabilities | 4,744,000 | 4,131,000 | 3,890,000 | 4,570,000 | 6,112,000 | 6,266,000 | 6,287,000 | 6,669,000 | 6,831,000 | 5,339,000 | 4,497,000 | 4,324,000 | 3,993,000 | 3,688,000 |
| net assets | -2,390,000 | -3,178,000 | -3,558,000 | -1,842,000 | -2,018,000 | -2,462,000 | -2,829,000 | -3,159,000 | -3,578,000 | -3,785,000 | -3,739,000 | -3,828,000 | -3,895,000 | -3,540,000 |
| total shareholders funds | -2,390,000 | -3,178,000 | -3,558,000 | -1,842,000 | -2,018,000 | -2,462,000 | -2,829,000 | -3,159,000 | -3,578,000 | -3,785,000 | -3,739,000 | -3,828,000 | -3,895,000 | -3,540,000 |
| Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 816,000 | 88,000 | -1,613,000 | 477,000 | 483,000 | 405,000 | 406,000 | 168,000 | 239,000 | -40,000 | 108,000 | 92,000 | -340,000 | -324,000 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | -3,000 | 327,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16,000 | 0 | 0 | 0 | 0 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5,000 | 4,000 | -3,000 | 4,000 | 0 |
| Debtors | 1,418,000 | 772,000 | -2,508,000 | -1,278,000 | 178,000 | 359,000 | -64,000 | 292,000 | 3,032,000 | -111,000 | -110,000 | 228,000 | -18,000 | 110,000 |
| Creditors | 256,000 | 157,000 | -15,000 | 30,000 | -48,000 | 219,000 | -271,000 | 258,000 | -13,000 | 32,000 | 11,000 | -13,000 | -9,000 | 76,000 |
| Accruals and Deferred Income | 253,000 | 144,000 | 87,000 | -66,000 | -50,000 | -2,675,000 | -147,000 | 2,723,000 | 67,000 | -20,000 | -192,000 | 257,000 | 17,000 | 193,000 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -96,000 | -56,000 | 967,000 | 1,719,000 | 207,000 | 52,000 | 2,857,000 | -2,739,000 | 104,000 | 33,000 | 111,000 | -318,000 | -165,000 | |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 104,000 | -60,000 | 2,708,000 | -1,648,000 | -56,000 | 2,435,000 | 0 | -2,848,000 | 1,757,000 | 830,000 | -3,542,000 | 424,000 | -40,000 | 3,419,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | -3,460,000 | 142,000 | 0 | 0 | 36,000 | -295,000 | -319,000 | 0 | 3,896,000 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | -25,000 | -35,000 | -103,000 | -159,000 | -39,000 | -38,000 | -76,000 | 23,000 | -32,000 | -22,000 | -19,000 | -25,000 | -3,000 | 0 |
| cash flow from financing | 79,000 | -95,000 | -855,000 | -1,807,000 | -95,000 | 2,397,000 | -40,000 | -2,892,000 | 1,406,000 | 808,000 | 335,000 | 399,000 | -43,000 | 203,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -17,000 | -151,000 | 112,000 | -88,000 | 112,000 | -13,000 | 12,000 | -35,000 | -1,333,000 | 912,000 | 368,000 | 173,000 | -36,000 | 38,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -337,000 | 337,000 | 0 |
| change in cash | -17,000 | -151,000 | 112,000 | -88,000 | 112,000 | -13,000 | 12,000 | -35,000 | -1,333,000 | 912,000 | 368,000 | 510,000 | -373,000 | 38,000 |
P&L
September 2022turnover
6.2m
+34%
operating profit
816k
+827%
gross margin
56.9%
+1.68%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
September 2022net assets
-2.4m
-0.25%
total assets
2.4m
+1.47%
cash
54k
-0.24%
net assets
Total assets minus all liabilities
euroclinics (uk) limited company details
company number
04499876
Type
Private limited with Share Capital
industry
86210 - General medical practice activities
incorporation date
July 2002
age
22
accounts
Total Exemption Full
ultimate parent company
previous names
euroclincs (uk) limited (September 2002)
incorporated
UK
address
beechwood hall kingsmead road, high wycombe, buckinghamshire, HP11 1JL
last accounts submitted
September 2022
euroclinics (uk) limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to euroclinics (uk) limited. Currently there are 1 open charges and 2 have been satisfied in the past.
euroclinics (uk) limited Companies House Filings - See Documents
| date | description | view/download |
|---|
